Seeking to Strengthen Market Competitiveness and Expand Services
On July 11, Lotte Biologics announced that it had signed a memorandum of understanding (MOU) for next-generation antibody-drug conjugate (ADC) toolbox collaboration with Aptis, an ADC development company under the Dong-A Socio Group.
James Park, CEO of Lotte Biologics (left), and Taedong Han, CEO of Aptis, are taking a commemorative photo at the business agreement signing ceremony. Lotte Biologics
Through this agreement, the two companies plan to jointly market Aptis's ApClick technology in conjunction with Lotte Biologics's conjugation production services at its Syracuse facility. They also aim to expand the scope of Lotte Biologics's ADC toolbox and strengthen their competitiveness in the domestic and global pharmaceutical and biotech markets for ADC-related new drug development and contract development and manufacturing organization (CDMO) services.
To build the ADC toolbox, a preliminary feasibility study on the ApClick technology will also be conducted at the Syracuse production facility. Currently, Lotte Biologics offers ADC toolbox services that allow customers to select and utilize a variety of technologies, including its proprietary SoluPlex technology.
Aptis possesses the third-generation linker technology platform, ApClick. ApClick enables selective drug conjugation at specific sites on the antibody Fc domain, eliminating the need to produce mutant antibodies. Its ability to secure a uniform drug-to-antibody ratio (DAR) ensures high quality, which is a key differentiator.
James Park, CEO of Lotte Biologics, stated, "This agreement will serve as an opportunity to maximize the technological competitiveness of both companies. We will strive to become a company that not only develops differentiated ADC therapeutics but ultimately contributes to improving patients' quality of life."
Taedong Han, CEO of Aptis, said, "We have high expectations for this agreement with Lotte Biologics, which has entered the ADC field based on years of expertise in antibody production. We hope that the combination of our technologies will enable us to secure competitiveness on the global stage."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
